Skip to main content

Table 1 Patient characteristics

From: MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma

  Primary tumour Liver metastases Clinical outcome  
No. Type Treatment Tumour burden Largest diameter Response Status Laboratory characterisation of exosomes
1 Choroidal I-125 10-24% 15 mm PR Alive 29 mo RNA, FACS, PCR
2 Choroidal En 25-50% 25 mm PR Dead 25 mo RNA
3 Choroidal I-125 + En 10-24% 45 mm PR Dead 17 mo RNA
4 Choroidal En <10% 20 mm PR Alive 17 mo EM
5 Choroidal En <10% 55 mm PR Dead 14 mo EC, RNA, PCR
6 Choroidal En 10-24% 35 mm PR Alive 13 mo EC, RNA, FACS
7 Choroidal I-125 <10% 23 mm SD Alive 13 mo EC, RNA, PCR
8 Choroidal Ru-106 25-50% 100 mm PD Alive 11 mo EC, RNA, PCR, FACS
9 Choroidal En <10% 40 mm PR Alive 10 mo EC, RNA, PCR
10 Choroidal Ru-106 + En <10% 30 mm SD Alive 7 mo EC
11 Choroidal En <10% 15 mm SD Alive 6 mo EC
12 Choroidal En 10-24% 25 mm PR Alive 5 mo EC
  1. I-125 = Iodine-125 brachytherapy; Ru-106 = Ruthenium-106 brachytherapy; En = Enucleation; PR = Partial response; SD = Stable disease; PD = Progressive disease; EC = Exosome concentration (peripheral blood); RNA = RNA concentration (liver perfusate); FACS = Flow cytometry (liver perfusate); PCR = Exosomal miRNA PCR array (liver perfusate); EM = Electron microscopy (liver perfusate).